Altimmune
$3.20
316
+$0.05+1.6% 11:10 Today
Statistics
Day High
3.26
Day Low
3.1
52W High
6.44
52W Low
2.56
Volume
4,014,010
Avg. Volume
4,239,014
Mkt Cap
614.54M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Dividends
0%Dividend Yield
Jan 17
$87.30
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A
Earnings
6AugExpected
Expected EPS
-0.151945
Actual EPS
N/A
Financials
-214,860.98%Profit Margin
Unprofitable41,000Revenue
-88.09MNet Income
Analyst Ratings
13.50Average Price Target
The highest estimate is 20.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy 75%
Hold 25%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ALT. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.6B
Moderna
MRNA
Mkt Cap31.65B
BioNTech
BNTX
Mkt Cap24.67B
Pfizer
PFE
Mkt Cap138.61B
Johnson & Johnson
JNJ
Mkt Cap633.19B
Inovio Pharmaceuticals
INO
Mkt Cap100.37M
GSK
GSK
Mkt Cap107.47B
Sanofi
SNY
Mkt Cap103.32B
About
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Show more...
CEO
Mr. Jerome Benedict Durso
Employees
59
Country
United States
ISIN
US02155H2004
Listings
0 Comments
Share your thoughts
FAQ
What is Altimmune stock price today?▼
The current price of ALT is $3.20 USD — it has increased by +1.6% in the past 24 hours. Watch Altimmune stock price performance more closely on the chart.
What is Altimmune stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Altimmune stocks are traded under the ticker ALT.
Is Altimmune stock price growing?▼
ALT stock has risen by +7.48% compared to the previous week, the month change is a +16.61% rise, over the last year Altimmune has showed a -33.47% decrease.
What is Altimmune market cap?▼
Today Altimmune has the market capitalization of 614.54M
When is the next Altimmune earnings date?▼
Altimmune is going to release the next earnings report on August 06, 2026.
What were Altimmune earnings last quarter?▼
ALT earnings for the last quarter are -0.18 USD per share, whereas the estimation was -0.24 USD resulting in a +25.71% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Altimmune revenue for the last year?▼
Altimmune revenue for the last year amounts to 41,000 USD.
What is Altimmune net income for the last year?▼
ALT net income for the last year is -88.09M USD.
Does Altimmune pay dividends?▼
Yes, ALT dividends are paid en. The last dividend per share was 87.3 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Altimmune have?▼
As of July 06, 2026, the company has 59 employees.
In which sector is Altimmune located?▼
Altimmune operates in the Health & Wellness sector.
When did Altimmune complete a stock split?▼
The last stock split for Altimmune was on September 14, 2018 with a ratio of 1:30.
Where is Altimmune headquartered?▼
Altimmune is headquartered in Gaithersburg, United States.